"Designing Growth Strategies is in our DNA"
B-cell lymphomas are a type of cancer which develops in the white blood cells called lymphocytes. According to the American Cancer Society, B-cell lymphomas make up to about 85% of the Non-Hodgkin lymphomas in the U.S. B-cell lymphomas can be classified into various types such as Diffuse Large B-cell lymphoma (DLBCL), follicular lymphoma, Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), Hairy cell leukemia, and others. Common symptoms of B-cell lymphomas are night sweats, fatigue, appetite loss, trouble in breathing, severe itching, and others.
Current treatment of B-Cell Lymphoma depends on the type of lymphoma and stage of the disease. Diffuse large B-cell lymphoma can be treated by a regimen of four drugs commonly known as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) and monoclonal antibody rituximab. Mantle cell lymphoma (MCL) can be treated using drugs such as lenalidomide, bortezomib, bendamustine, ibrutinib, and others.
According to the National Cancer Institute, the number of new cases of diffuse large B-cell lymphoma was 5.6 per 100,000 men and women every year, making it an area for increased research. Various pharmaceutical companies and research institutes are developing new treatment options for B-Cell Lymphomas. For instance; CPI-1205, which is being studied by Constellation Pharmaceuticals, is currently in phase 1 clinical trials for the treatment of B-cell Lymphomas.
To know how our report can help streamline your business, Speak to Analyst
At present, around 48% of the pipeline candidates for B-Cell Lymphomas are in phase 1 clinical stage. Majority of the studies are sponsored by the pharmaceutical industry.
The report on ‘B-Cell Lymphomas – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for B-Cell Lymphomas. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for B-Cell Lymphomas.
The report on ‘B-Cell Lymphomas – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.